A pharmacist who transfers a controlled substance prescription to another pharmacy without following the exact federal requirements creates a recordkeeping gap that a Drug Enforcement Administration (DEA) diversion investigator can document in a routine inspection. The rule turns on the schedule. A Schedule II prescription generally cannot move between pharmacies by phone or on paper, while prescriptions in Schedules III, IV, and V can be transferred for refill purposes under 21 CFR 1306.25. A narrower 2023 amendment to 21 CFR 1306.08 opened a one-time electronic pathway for Schedule II prescriptions as well. Getting the schedule, the one-time limit, or the paperwork wrong is exactly the kind of gap an audit finds first.
Schedule II Prescriptions and the Narrow Transfer Exception
For decades, a Schedule II prescription could not be transferred from one pharmacy to another under any circumstance; the patient had to return to the prescriber for a new prescription or have the original pharmacy fill it. That changed on August 28, 2023, when an amendment to 21 CFR 1306.08 took effect. Under the amended rule, a retail pharmacy may transfer an electronic prescription for a Schedule II, III, IV, or V controlled substance to another DEA-registered retail pharmacy for initial dispensing, but only once, only at the patient's request, and only where the transfer is communicated directly between two licensed pharmacists. The prescription must move in its original electronic form; a pharmacy cannot convert it to a fax or a paper printout and call that a compliant transfer. Because Schedule II prescriptions carry no authorized refills, this one-time transfer is also the only transfer that prescription will ever see.
Transferring Schedules III, IV, and V Under 21 CFR 1306.25
Prescription information for a Schedule III, IV, or V controlled substance can be transferred between pharmacies for refill purposes under 21 CFR 1306.25, and the rule is not limited to electronic prescriptions. The default is still one-time only: once a pharmacy transfers the remaining refills to a receiving pharmacy, the originating pharmacy can no longer fill that prescription. The exception is pharmacies that electronically share a real-time, online database, which may transfer a prescription back and forth up to the maximum number of refills the prescriber authorized. Outside that shared-database exception, a second transfer of the same prescription is not a paperwork technicality. It is a violation of the regulation.
A Schedule II prescription cannot be transferred between pharmacies by phone or on paper. The only lawful pathway is the one-time electronic transfer for initial dispensing that DEA created in August 2023, and it does not extend to a second transfer or to a paper prescription.
Records Both Pharmacies Must Keep
21 CFR 1306.25 requires the transferring pharmacist to void the original prescription, or note the transfer electronically, and record the receiving pharmacy's name, address, and DEA registration number, the receiving pharmacist's name, and the date of the transfer. The receiving pharmacist must record the original prescription's issuance date and authorized refills, the date and location of every prior fill, and the name of the transferring pharmacist. Under the 2023 amendment to 21 CFR 1306.08, both pharmacies instead keep the electronic transfer record itself. Either way, the retention period is the same: both the transferring and the receiving pharmacy must maintain the record for two years.
Where Transfer Errors Become DEA Exposure
A missing DEA registration number on a transfer record, a prescription filled twice because two pharmacies each believed they held the only valid copy, or an electronic transfer converted to a fax are recordkeeping failures a diversion investigator can document during a DEA inspection. Repeated or unexplained transfer discrepancies feed directly into the same inventory reconciliation process that drives broader audit findings, and in a pharmacy that already has other compliance gaps, they can become one more exhibit supporting an order to show cause or, in an urgent case, an immediate suspension order.
Why Early Legal Counsel Is Critical
It is critical that a pharmacy contact experienced healthcare defense counsel as soon as a controlled substance transfer becomes an issue in a DEA inspection or audit, rather than after the agency has already drawn its conclusions. Early legal intervention can protect the pharmacy's rights, shape how the pharmacy responds to the agency's requests, and preserve the defenses available before an inspection finding hardens into a registration action. Delaying legal representation can significantly affect the outcome of the matter.
How Health Law Alliance Can Help
Health Law Alliance has represented 2,500+ clients over 25+ years, including pharmacies facing DEA scrutiny over controlled substance recordkeeping. Our DEA defense attorneys review transfer records before an inspection becomes a referral, and represent pharmacies through an order to show cause or registration action once one is issued. Contact Health Law Alliance for a free, confidential consultation.
